AVXL received a $15.00 price objective from investment analysts at Maxim Group in a note issued to investors on Thursday. The brokerage currently has a “buy” rating on the stock. Maxim Group’s target price would indicate a potential upside of 271.29% from the company’s previous close.

Separately, FBR & Co set a $10.00 target price on Anavex Life Sciences Corp. and gave the stock a “buy” rating in a report on Thursday, September 29th.

Schwab Charles Investment Management Inc. purchased a new stake in
Anavex Life Sciences Corp. during the second quarter valued at approximately $313,000. California State Teachers Retirement System purchased a new stake in Anavex Life Sciences Corp. during the second quarter valued at approximately $418,000. Bank of New York Mellon Corp increased its stake in Anavex Life Sciences Corp. by 136.8% in the second quarter. Bank of New York Mellon Corp now owns 129,276 shares of the company’s stock valued at $790,000 after buying an additional 74,682 shares in the last quarter. Rhumbline Advisers increased its stake in Anavex Life Sciences Corp. by 13.1% in the third quarter. Rhumbline Advisers now owns 35,476 shares of the company’s stock valued at $129,000 after buying an additional 4,100 shares in the last quarter. Finally, State Street Corp increased its stake in Anavex Life Sciences Corp. by 349.4% in the second quarter. State Street Corp now owns 88,972 shares of the company’s stock valued at $544,000 after buying an additional 69,172 shares in the last quarter. Hedge funds and other institutional investors own 11.57% of the company’s stock.